Loading
Catalyst Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 Feb 2016.
Catalyst Pharmaceuticals, Inc.: what insiders have been doing
Catalyst Pharmaceuticals, Inc., founded in 2002, is a Healthcare & Pharma company based in Coral Gables, United States. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Catalyst Pharmaceuticals, Inc. logged 56 filings by 13 insiders.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €784k. Elsbernd Brian filed the largest sale, €784k, on 14 November 2025.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 56 filings, this issuer sits above that mark. Our records for Catalyst Pharmaceuticals, Inc. go back to 2016, with 4 purchases and 31 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 589.0 m USD and net income of 214.3 m USD.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
259
Thresholds
n/a
Buy Volume
n/a
4 ops. · all time
Sell Volume
€19M
31 ops. · all time
Who traded when
BuySaleBrian Elsbernd1 sale
Jeffrey Del Carmen1 sale
Patrick J. Mcenany1 sale
Preethi Sundaram1 sale
Richard J. Daly1 sale
Since the insiders bought
- +7.6%Entry US$1.05 · Close at T+365 US$1.13
- -39.8%Entry US$1.86 · Close at T+365 US$1.12
- -39.8%Entry US$1.86 · Close at T+365 US$1.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,725 of 24,161 companies
76.6
score / 100
Value59
Quality94
FCF yld5.4%
Earn yld5.6%
EV/EBITDA13.0x
ROE24%
Gross mgn85%
Net mgn36%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$31.49
Analyst consensus
3 analysts2.67/5
US$31.50Target US$31.67(+1%)US$32.00
Income statement
RevenueUS$589M
Gross profitUS$501.7M85% margin
EBITDAUS$295.7M50% margin
Net incomeUS$214.3M37.1% margin
Valuation
PER (trailing)18.2x
PER (forward)9.9x
P/Book3.8x
Beta0.74
Balance sheet & cash
Market capUS$3.9B
Total debtUS$2.8M
Free Cash FlowUS$208.6M
Debt / Equity0%
Profitability & ownership
ROE24.5%
ROA16.3%
% insiders5.6%
% institutions90.0%
Last declaration on 17 July 2026
Declarations259 total
271,266 shares@ US$31.500.22% mcap77.9% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000173:0
14,337 shares@ US$31.500.012% mcap20.8% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000174:0
498,773 shares@ US$31.500.41% mcap91.8% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000175:0
4,171,559 shares@ US$31.503.39% mcap95.9% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000179:0
1,093,803 shares@ US$31.500.89% mcap85.3% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000180:0
476 shares@ US$31.500.0004% mcap100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000181:0
3,773 shares@ US$31.500.0031% mcap100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000183:0
2,309 shares@ US$31.500.0019% mcap100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000171:0
242,501 shares@ US$31.500.20% mcap77.7% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000176:0
3,694 shares@ US$31.500.0030% mcap23.7% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000177:0
13,665 shares@ US$31.500.011% mcap100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000178:0
54,804 shares@ US$31.500.045% mcap76.7% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000182:0
383,314 shares@ US$31.500.31% mcap94.9% of flowCommon Stock, par value $0.001 per shareSEC:0001161697-26-000184:0
3,052 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-26-000132:0
743 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-26-000132:1
687 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-26-000044:0
7,139 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-26-000022:0
42,105 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-26-000021:0
1,334 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000488:0
524 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000488:1
8,667 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000489:0
3,839 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000489:1
1,334 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000490:0
6,667 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000491:0
2,623 sharesCommon Stock, par value $0.001 per shareSEC:0001161697-25-000491:1
25 of 259 declarations
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker CPRX. Headquartered in Coral Gables, Florida, United States, Catalyst is a niche specialty pharma group focused on rare diseases and difficult-to-treat disorders. Incorporated in Delaware in 2006, the company evolved from a development-oriented biotech into a commercial-stage business that now derives most of its revenue from marketed products.
Catalyst’s business model is centered on in-licensing, acquiring, and commercializing specialized medicines with durable regulatory and commercial advantages. Its flagship product is FIRDAPSE® (amifampridine), approved in the United States for Lambert-Eaton myasthenic syndrome (LEMS) and launched commercially in 2019. The company also markets AGAMREE® (vamorolone), a rare-disease therapy with a pediatric focus, and FYCOMPA® (perampanel), which Catalyst acquired for the U.S. epilepsy market. This portfolio reflects a clear strategy: build value by acquiring immediately commercializable or near-commercial assets in orphan and specialty indications.
Read moreShow less
From a competitive standpoint, Catalyst stands out for its concentrated but differentiated portfolio, supported by deep regulatory, commercial, and distribution expertise in rare diseases. It is not a broad-based large-cap pharma company; rather, it seeks to create shareholder value through focused execution, sales-force optimization, and disciplined product expansion. The company’s geographic footprint remains primarily U.S.-centric, although it has selective international reach through licensing and supply arrangements, including Canada for FIRDAPSE.
Recent developments indicate a continued emphasis on commercial execution and portfolio management. SEC filings and company updates show revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with a 2025 commercial realignment designed to sharpen support for the two key brands. At the same time, FYCOMPA has faced pressure following loss of exclusivity, reinforcing Catalyst’s need to replenish the portfolio with new accretive assets. For investors, CPRX is best viewed as a specialty rare-disease platform with a relatively defensive profile, but one that remains dependent on a small number of key products and on management’s ability to secure and integrate additional commercial assets.
